Home
Inmunotek

Inmunotek Market Share Analysis for June 2026

Inmunotek es un laboratorio farmacéutico que desarrolla, fabrica y comercializa productos en el campo de la alergia e inmunología. Tiene su sede en Madrid.

Health > Health - Other

Domaininmunotek.com

Year Founded1992

Employees201 - 500

Annual Revenue$15M - $25M

Inmunotek

Inmunotek (including company regionals)

inmunotek.com

See more website traffic and engagement information

Inmunotek Revenue up to June 2026 is 15M - 25M

revenue generated by Inmunotek top domains

Inmunotek top domains revenue over 3 years

Revenue for Inmunotek top domains

inmunotek.com15M - 25M

See more with Sales Intelligence

Total visits to Inmunotek's top domains

Understand Inmunotek market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

inmunotek.com12.9K

See more with Sales Intelligence

Avg. visit duration in Inmunotek's top domains

Analyze Inmunotek engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

inmunotek.com00:00:21

See more with Sales Intelligence

Avg. pageviews on Inmunotek's top domains

See how Inmunotek keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

inmunotek.com1.90

See more with Sales Intelligence

Inmunotek top competitors by domain

Top similar sites in June 2026, ranked by their affinity

immunotec.comCompany NameImmunotecEmployees201 - 500HQCanada, Alt Quebec CityAnnual revenue$15M - $25MTotal visits179.9KHealth > Health - Other

Top technologies used by Inmunotek

These are the website technologies, by industry, used by Inmunotek top domains

Advertising (4)

Google Adsense

Widget (4)

Twemoji

Email Services (3)

G Suite

Social (3)

Instagram

More Technologies

8

See all

News & Signals from Inmunotek

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsInmunotek receives award National Innovation Award in the SME (Small and Medium-Sized Entities) category.The event was chaired by their Majesties the Kings of Spain, and INMUNOTEK was awarded the National Innovation Award in the SME (Small and Medium-Sized Entities) category.

NewsInmunotek is developing Expanded Access Program for the unlicensed bacterial vaccine Uromune on Dec 12th '19.myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters in Madrid, Spain – a global player in allergy and immunity-based bacterial vaccines, today announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.

NewsInmunotek is developing Uromune.Inmunotek is developing a glycerinated suspension containing whole cell-inactivated bacteria, Uromune (MV140) subjected to be administered by spraying over for sublingual administration.